What Is Lonapegsomatropin? Definition and What Research Reports

Lonapegsomatropin is a long-acting, once-weekly prodrug of somatropin — the recombinant form of human growth hormone (hGH, a 191-amino-acid protein). In the molecule, unmodified somatropin is bound to a carrier via a cleavable linker; under physiological conditions the linker slowly hydrolyses and releases the native hormone, so a single weekly injection is intended to substitute for the daily injections historically used in growth hormone replacement. A 2022 review described lonapegsomatropin as having received a pediatric first approval for children with growth failure due to inadequate secretion of endogenous growth hormone (PMID 34709591). It is a pharmaceutical product, not a research-only or compounded peptide, and the term appears in the literature almost exclusively in the context of clinical trials in growth hormone deficiency (GHD).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Nothing here describes how any product should be used.

What Class of Molecule It Is

Lonapegsomatropin belongs to the class of long-acting growth hormone (LAGH) products. Unlike a peptide analogue whose amino-acid sequence has been altered, a prodrug design keeps the parent hormone chemically intact and instead slows its release. A 2022 spotlight review characterised lonapegsomatropin as a once-weekly injection releasing unmodified somatropin and summarised its development programme in pediatric growth hormone deficiency (PMID 35791404). This distinguishes it conceptually from other weekly growth hormone products such as somapacitan and somatrogon, which use albumin binding and peptide extension respectively; a 2024 systematic literature review and network meta-analysis compared somapacitan with somatrogon and lonapegsomatropin in pediatric growth hormone deficiency (PMID 39261416).

Where the Term Comes From

"Lonapegsomatropin" follows international nonproprietary naming conventions: the stem -somatropin identifies recombinant human growth hormone, and the infix -peg- indicates polyethylene glycol conjugation. The name therefore encodes the molecule's two components — a PEG carrier and the somatropin payload — joined by the transient linker described in the pediatric approval review (PMID 34709591).

How the Term Is Used in Research

In the published literature, lonapegsomatropin appears as the investigational or approved comparator in a series of clinical trials with "GHt" capitalisation in their names — heiGHt, fliGHt, enliGHten and foresiGHt — each addressing a different population or question. Researchers have used the term in four recurring contexts:

• Treatment-naïve pediatric GHD, where weekly lonapegsomatropin was compared with daily somatropin in a phase 3 trial (PMID 34272849).
• Switching studies, in which children already receiving daily somatropin transitioned to the weekly product (PMID 35263755).
• Long-term extension follow-up, reported at two years and again at up to six years (PMID 35428884, PMID 40049149).
• Adult growth hormone deficiency, addressed in the foresiGHt trial (PMID 41420532).

The term also appears in pharmacokinetic and modelling work — for example, a 2022 analysis in the Journal of the Endocrine Society addressed average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency, reflecting the fact that a weekly release profile produces fluctuating IGF-1 rather than the steadier pattern of daily injections (PMID 34913019).

What the Published Literature Reports

The pivotal phase 3 heiGHt trial evaluated weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency and reported annualised height velocity as its primary outcome in comparison with daily somatropin (PMID 34272849). The fliGHt trial examined children switching to weekly lonapegsomatropin from daily somatropin and reported on growth and safety outcomes after the transition (PMID 35263755); a separate 2025 report in the Journal of Pediatric Endocrinology & Metabolism described clinical outcomes of switching to lonapegsomatropin from somatropin in pediatric growth hormone deficiency in a real-world setting (PMID 39843388).

Longer-term data came from the enliGHten extension. Two-year results reported safety and efficacy in children with growth hormone deficiency (PMID 35428884), and the final results described sustained height improvements for up to six years of treatment (PMID 40049149). In adults, the foresiGHt trial reported efficacy and safety of once-weekly lonapegsomatropin in adults with growth hormone deficiency (PMID 41420532). Beyond GHD, a phase 2 trial called COACH reported 52-week results for navepegritide combined with lonapegsomatropin in children with achondroplasia (PMID 42144862).

Trial Landscape at a Glance

Tolerability and Adverse Events: What Studies Report

Safety reporting accompanied each of the main trials. The enliGHten two-year report addressed safety alongside efficacy in children with growth hormone deficiency (PMID 35428884), and the foresiGHt trial reported safety outcomes in adults (PMID 41420532). A 2023 case report in Hormone Research in Paediatrics described severe transient hyperglycemia in a child with obesity treated with weekly lonapegsomatropin, illustrating that individual case findings also appear in the literature (PMID 37015214). The 2024 network meta-analysis placed lonapegsomatropin alongside somapacitan and somatrogon in an indirect comparison of efficacy and safety in pediatric growth hormone deficiency (PMID 39261416).

How It Differs From "Research Peptides"

Lonapegsomatropin is a regulated prescription biologic with a pediatric first approval, not a research-chemical peptide sold for laboratory use (PMID 34709591). Its evidence base consists of registrational phase 3 trials with prespecified endpoints rather than preclinical or observational reports. Readers encountering the name in peptide discussions are usually seeing it referenced as a comparator or as an example of prodrug chemistry applied to a protein hormone, as the 2022 spotlight review outlined (PMID 35791404).

Key Points

1. Lonapegsomatropin is a once-weekly prodrug that releases unmodified somatropin (PMID 35791404).
2. It received a pediatric first approval for growth hormone deficiency (PMID 34709591).
3. Trials spanned treatment-naïve children, switch populations, multi-year extension follow-up and adults (PMID 34272849, PMID 40049149, PMID 41420532).

This entry is definitional and summarises what researchers reported; it does not describe or endorse any use. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about growth hormone deficiency or any prescribed therapy.

References

• Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Lonapegsomatropin: Pediatric First Approval (Paediatric Drugs, 2022)
• Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients (Drug Design, Development and Therapy, 2022)
• Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial (Hormone Research in Paediatrics, 2022)
• Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results (Hormone Research in Paediatrics, 2026)
• Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency (Journal of the Endocrine Society, 2022)
• Clinical outcomes of switching to lonapegsomatropin from somatropin for treatment of pediatric growth hormone deficiency (Journal of Pediatric Endocrinology & Metabolism, 2025)
• Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis (Advances in Therapy, 2024)
• Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial (European Journal of Endocrinology, 2026)
• Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity (Hormone Research in Paediatrics, 2023)